Reneo Pharmaceuticals – Addressing The Unmet Need of Rare Genetic Mitochondrial Disease

Gregory Flesher is President and CEO of Reneo Pharmaceuticals, a clinical-stage pharmaceutical company tackling the significant unmet need of developing therapies for patients with rare genetic mitochondrial diseases. The company’s lead candidate, REN001, is currently being investigated in the Phase 2b STRIDE clinical trial for patients with Primary Mitochondrial Myopathies (PMM). He talks about the ongoing development of REN001 and what the future holds for Reneo Pharmaceuticals.

Greg is the President and Chief Executive Officer of Reneo Pharmaceuticals and serves as a member of the company’s Board of Directors. Greg brings to Reneo more than 25 years of biopharmaceutical industry experience in executive management, corporate and business development, operations, sales and marketing, and clinical development. He has been closely involved with several novel development programs resulting in multiple product approvals and successful commercial launches in the U.S. and Europe.

Prior to joining Reneo, Greg was Chief Executive Officer and a member of the Board of Directors of Novus Therapeutics (Nasdaq: NVUS), a clinical-stage pharmaceutical company he took public in 2017 and led through the transformational acquisition of Anelixis Therapeutics in 2020. Prior to Novus, Greg was Chief Business Officer of publicly traded Avanir Pharmaceuticals (AVNR), a commercial-stage pharmaceutical company, where he led corporate and business development as well as corporate operations through the $3.5 billion acquisition of the company by Otsuka Pharmaceuticals in 2015. From 1995 to 2006, Greg held multiple leadership roles at Intermune (acquired by Roche), Amgen, and Eli Lilly and Company.

Greg received his B.S. in biology from Purdue University and studied biochemistry and molecular biology at Indiana University School of Medicine.